Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.50 |
| ▸ | GPR88 | Q9GZN0 | 3/20 | 0.42 |
| ▸ | ACACB | O00763 | 8/20 | 0.42 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17571713 | 0.91 | KAT2B (0.52) | KAT2BGPR88ACACBPARP15PARP10 | |
| SCHEMBL19402481 | 0.84 | KAT2B (0.49) | KAT2BGPR88ACACBPARP15PARP10 | |
| SCHEMBL19402526 | 0.83 | KAT2B (0.56) | KAT2BGPR88ACACBPARP15PARP10 | |
| SCHEMBL19397749 | 0.82 | KAT2B (0.55) | KAT2BGPR88ACACBPARP15PARP10 | |
| SCHEMBL10014749 | 0.77 | PARP15 (0.50) | GPR88ACACBPARP15PARP10PARP2 | |
| SCHEMBL30932889 | 0.74 | PARP15 (0.51) | GPR88ACACBPARP15PARP10PARP2 | |
| SCHEMBL17246825 | 0.74 | PARP15 (0.51) | GPR88ACACBPARP15PARP10PARP2 | |
| SCHEMBL7601081 | 0.74 | PARP15 (0.51) | GPR88ACACBPARP15PARP10PARP2 | |
| SCHEMBL19876587 | 0.74 | PARP15 (0.51) | GPR88ACACBPARP15PARP10PARP2 | |
| SCHEMBL19397702 | 0.74 | SLC2A1 (0.47) | KAT2BTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | HDAC10, HDAC6, HDAC1 | KAT2B 41/4885GPR88 1375/4885ACACB 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.